|
|
14 Cambridge Center
Cambridge, MA 02142 USA
phone:(617) 679-2000
fax:(617) 679-2617
|
|
| Symbol |
BIIB |
| Exchange |
NASDAQ |
| Founded |
1978 |
| Employees |
|
|
|
| biogenidec.com/
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Drug discovery, R & D, biomanufacturing, tied to a global commercial infrastructure. |
|
| Management |
| James C. Mullen, our President and Chief Executive Officer; Susan H. Alexander, Executive Vice President, General Counsel and Corporate Secretary; Paul J. Clancy, Executive Vice President and Chief Financial Officer; John M. Dunn, Executive Vice President; Robert A. Hamm, Chief Operating Officer |
| |
|
|
|
|
|
|
|
| Keywords |
| natalizumab, leukoencephalopathy, opportunistic, anaphylaxis, immunosuppressants |
|
|
|
| Description |
|
Biogen Idec Inc. has many products and capabilities in oncology, neurology and immunology. The company's core capabilities include drug discovery, research, development, biomanufacturing, and a global commercial infrastructure. |
|
| Products / Services |
RITUXAN? (rituximab), ZEVALIN? (ibritumomab tiuxetan), AVONEX? (Interferon beta-1 a), AMEVIVE? (alefacept)
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
